Eupraxia Pharmaceuticals initiated with a Buy at Rodman & Renshaw

Rodman & Renshaw analyst Brandon Folkes initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy rating and $9 price target Eupraxia is a delivery technology innovator, utilizing its proprietary DiffuSphere technology, which employs a diffusion-based approach to drug delivery, the analyst tells investors in a research note. The firm says the company has demonstrated proof of concept and sees potential for expanding the platform to new therapeutic candidates, positioning DiffuSphere as a “versatile and groundbreaking delivery technology.”